Tryptophan (W) at position 37 of murine IL-12/IL-23 p40 is mandatory for binding to IL-12Rβ1 and subsequent signal transduction

Jacqueline Georgy¹, Yvonne Arlt¹, Jens M. Moll¹, Meryem Ouzin¹, Hendrik T. Weitz¹, Lothar Gremer^{2, 3}, Dieter Willbold^{2, 3}, Joachim Grötzinger⁴, Felix Thives-Kurenbach¹, Jürgen Scheller¹ and Doreen M. Floss^{1*}

From the ¹Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ²Institute of Biological Information Processing (IBI-7: Structural Biochemistry) and JuStruct: Jülich Center for Structural Biology, Forschungszentrum Jülich, Jülich, Germany, ³Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany and the ⁴Institute of Biochemistry, Medical Faculty, Christian-Albrechts-University Kiel, Kiel, Germany

Supporting Information

Figure S1: Alignment of murine and human p40.

Figure S2: Dose-response analysis of HIL-23 variants on cellular proliferation of Ba/F3-gp130-mIL-12R β 1-mIL-23R cells

Figure S3: Purification of cytokines using Strep-Tactin[®]XT 4Flow[®] columns.

Figure S4: Far-UV CD spectroscopy of HIL-23 and HIL-12 variants

Figure S5: Receptor binding of HIL-23 and HIL-12 variants.

Figure S6: Interaction of cytokines with respective receptors.




Figure S1: Alignment of murine and human p40. A, Superpositioning of human p40 (hp40) (PDB 6WDQ) and a model of murine p40 (mp40). Ustekinumab binding epitope is highlighted (red). Corresponding residues of mIL-12p40 are indicated (magenta). For comparison, a model of mp40D36K/W37K/T38K is displayed in an additional panel. B, alignment of murine and human p40. Signal peptides M1 to A22 are underlined. N-terminal deletion variant Δ M23-D29 and Δ Y31-T38 are highlighted in green and blue. Three loops (W38-M46, L62-L69 and T76-Y88) contribute to the binding epitope of Ustekinumab (1). Hypothesized residues in D1 of human p40, which might be important for binding to IL-12R β 1 are shown in red Glassman 2021. Alanine substitutions, presented in purple, have been introduced into two loops of p40, which reduced the potency of IL-12 and IL-23 (2).




Figure S2: Dose-response analysis of HIL-23 variants on cellular proliferation of Ba/F3-gp130-mIL-12R β 1-mIL-23R cells. The cells were cultured for 3 days in the presence of increasing concentrations of the indicated cytokines (0.04 to 20% conditioned cell culture supernatant of transfected CHO-K1 cells). The results of one representative experiment of three (A) or two (B) are shown. Error bars represent S.D. for technical replicates.




Figure S3: Purification of cytokines using Strep-Tactin®XT 4Flow® columns. Purity of the Expi cell produced murine p40, p40D36K/W37K/T38K, HIL-12, HIL-12D36K/W37K/T38K, HIL-23 and HIL-23D36K/W37K/T38K was analyzed by SDS-PAGE on reducing gels via Coomassie brilliant blue staining. M, molecular weight marker; SN, cell culture supernatant; FT, flow through; E1-E4, elution fraction 1 to 4; D1, D3, D7, cell culture supernatant of Expi cells from day 1, 3 or 7.




Figure S4: Far-UV CD spectroscopy of HIL-23 and HIL-12 variants. The far-UV spectra of HIL-23 (A) and HIL-23D36K/W37K/T38K (B), or HIL-12 (C) and HIL-12D36K/W37K/T38K (D) indicate that the wild type proteins and their KKK mutants have a highly similar overall secondary structure. Y-axis, θ_{MRW} in deg x cm² x dmol⁻¹; x-axis, wavelength in nm.




Figure S5. Receptor binding of HIL-23 and HIL-12 variants. A, surface plasmon resonance analysis of HIL-23 binding to IL-23R-Fc. IL-23R-Fc was captured on a ProtA chip and increasing concentrations of HIL-23 and HIL-23D36K/W37K/T38K were injected (15-1000 nM). B, surface plasmon resonance analysis of HIL-12 binding to IL-12R β 2-Fc. IL-12R β 2-Fc was captured on a ProtA chip and increasing concentrations of HIL-12 and HIL-12D36K/W37K/T38K were injected (0.3-5 nM). Sensorgrams in response units (RU) over time are depicted as colored lines, fit data are displayed as black lines.




Figure S6: Interaction of cytokines with respective receptors. A, co-IP of FLAG-tagged murine HIL-23 variants (wild-type, D36K, W37K and T38K) and full-length mIL-23R. The position of mIL-23R and HIL-23 variants is indicated by arrows. One of two independent experiments is shown. B, co-IP of FLAG-tagged murine HIL-23 variants (wild-type, D36K/W37K/T38K, D36K/W37K, W37K/T38K) and full-length mIL-23. The position of mIL-23R and HIL-23 variants is indicated by arrows. One of two independent experiments is shown. C, co-IP of FLAG-tagged murine HIL-12 variants (wild-type, D36K/W37K/T38K, Y185R) and full-length mIL-12R β 2. The position of mIL-12R β 2 and HIL-12 variants is indicated by arrows. One of two independent experiments is shown. D, co-IP of FLAG-tagged human p40 variants (wild-type, D36K/W37K/Y38K) and full-length hIL-23R. The position of hIL-23R and hp40 variants is indicated by arrows. One of two independent experiments is shown.

References

- 1. Luo, J., Wu, S. J., Lacy, E. R., Orlovsky, Y., Baker, A., Teplyakov, A., Obmolova, G., Heavner, G. A., Richter, H. T., and Benson, J. (2010) Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. *J. Mol. Biol.* **402**, 797-812
- 2. Glassman, C. R., Mathiharan, Y. K., Jude, K. M., Su, L., Panova, O., Lupardus, P. J., Spangler, J. B., Ely, L. K., Thomas, C., Skiniotis, G., and Garcia, K. C. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. *Cell* **184**, 983-999 e924